News

Curated Newsfeed

  • Wellcome awards CHF 14 million for BioVersys’ BV100 Phase 2b study

    BioVersys’ lead asset BV100, an innovative anti-infective developed for hospital infections caused by Acinetobacter baumannii, including carbapenem resistant strains (CRAB), has been selected to participate…

    startupticker.ch

  • AstraZeneca acquires SixPeaks for up to USD 300 million

    Following an initial investment of USD 15 million in 2024, AstraZeneca has acquired Basel-based SixPeaks Bio AG. SixPeaks is investigating potential therapies for weight-management with…

    startupticker.ch

  • Positrigo on a growth momentum in the US

    One year following the acquisition of its first customer in the US market, Positrigo continues to strengthen its position in America. The company has installed…

    startupticker.ch

DTN Highlights